Top Markets
Coin of the day
EFFECTOR Therapeutics, Inc. EFFECTOR Therapeutics, Inc.

EFFECTOR Therapeutics, Inc.

EFTRW
Rangering i aksjer #42260
eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the... eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.
Aksjekurs
$0.0006
Sist synkronisert: 2025-11-25
Markedsverdi
$2.82K
Endring (1 dag)
59,900.00%
Endring (1 år)
59,900.00%
Land
US
Handel EFFECTOR Therapeutics, Inc. (EFTRW)

Kategori

Aksjeprishistorikk for EFFECTOR Therapeutics, Inc. (EFTRW)
Høyeste sluttskurs: $0.00 den 2025-11-01

Laveste sluttskurs: $0.98 den 2021-03-01
Aksjeprishistorikk for EFFECTOR Therapeutics, Inc. fra 2021 til 2026
Årlig aksjeprisytelse
År Ytelse
2026 (TTM) 0.00%
2025 59,900.00%
2024 -100.00%
2023 12.00%
2022 -85.79%
2021 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$527.87 33.33%
US
$873.57 35.10%
NL
$736.38 7.69%
CH
$263.09 18.09%
BE
$1.07K -7.57%
KR